Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development

André L Mencalha¹
Stephany Corrêa²
Eliana Abdelhay²

¹Biophysics and Biometry Department, Roberto Alcântara Gomes Biology Institute, Rio de Janeiro’s State University (UERJ), Rio de Janeiro, Brazil; ²Bone Marrow Transplantation Unit (CEMO), National Cancer Institute (INCA), Rio de Janeiro, Brazil

Abstract: Calcium-dependent protein kinases (PKCs) function in a myriad of cellular processes, including cell-cycle regulation, proliferation, hematopoietic stem cell differentiation, apoptosis, and malignant transformation. PKC inhibitors, when targeted to these pathways, have demonstrated efficacy against several types of solid tumors as well as leukemia. Chronic myeloid leukemia (CML) represents 20% of all adult leukemia. The aberrant Philadelphia chromosome has been reported as the main cause of CML development in hematopoietic stem cells, due to the formation of the BCR-ABL oncogene. PKCs and BCR-ABL coordinate several signaling pathways that are crucial to cellular malignant transformation. Experimental and clinical evidence suggests that pharmacological approaches using PKC inhibitors may be effective in the treatment of CML. This mini review summarizes articles from the National Center for Biotechnology Information website that have shown evidence of the involvement of PKC in CML.

Keywords: PKC signaling, chronic myeloid leukemia, pharmacological inhibitors, malignant transformation

Introduction

The calcium-dependent protein kinase (PKC) superfamily represents a group of eleven serine/threonine-kinase isoforms.¹ Initially thought to be exclusively calcium (Ca²⁺)-and diacylglycerol (DAG)-dependent,² PKCs can also be regulated by different lipid secondary messengers, including phosphatidylserine (PS) and sphingolipids. PKCs are subdivided into three classes that comprise different isoforms with particular features: 1) the classic PKCs (PKCα, PKCβI, PKCβII, PKCγ), which are Ca²⁺- dependent and activated by both PS and DAG; 2) the novel PKCs (PKCδ, PKCε, PKCη, PKCμ, PKCθ), which are only regulated by PS and DAG; and 3) atypical PKCs (PKCζ, PKCλ), which are Ca²⁺- and DAG-independent. These different classes are grouped according to protein-domain similarities and/or different activation signals (Figure 1).³

The different PKC isoforms are responsible for modifying the activities of a broad range of cellular proteins, including receptors, metabolic enzymes, cytoskeletal proteins, and transcription factors.⁴ PKC activation is mediated by phosphorylation, which plays a crucial role in the regulation of all PKCs and results in subcellular translocations to or from specific anchoring/scaffolding proteins.⁵ Once activated, PKC proteins remain active for a long time until the cytoplasmic Ca²⁺ signal is diminished.⁶ PKCs are involved in several cellular processes, such as cell proliferation, differentiation,
PKC class and protein domains

<table>
<thead>
<tr>
<th>PKC class and protein domains</th>
<th>PKC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conventional</td>
<td>α (alpha)</td>
</tr>
<tr>
<td></td>
<td>β1 (beta1)</td>
</tr>
<tr>
<td></td>
<td>β2 (beta2)</td>
</tr>
<tr>
<td></td>
<td>γ (gamma)</td>
</tr>
<tr>
<td>Novel</td>
<td>δ (delta)</td>
</tr>
<tr>
<td></td>
<td>ε (epsilon)</td>
</tr>
<tr>
<td></td>
<td>η (eta)</td>
</tr>
<tr>
<td></td>
<td>μ (mu)</td>
</tr>
<tr>
<td></td>
<td>θ (theta)</td>
</tr>
<tr>
<td>Atypical</td>
<td>ζ (zeta)</td>
</tr>
<tr>
<td></td>
<td>ι/λ (iota/lambda)</td>
</tr>
</tbody>
</table>

Pseudogene site
PS- and DAG-binding site
Ca\(^{2+}\)-binding site
ATP-binding site
C\(_{2}\) -like
Catalytic core

**Figure 1** Scheme of protein kinase C (PKC) superfamily. This family comprises different isoforms grouped into three classes (classic, novel, and atypical) that share structural features.

**Abbreviations:** PS, phosphatidylserine; DAG, diacylglycerol; ATP, adenosine triphosphate.

polarity, and survival, and they are also important for the establishment and progression of malignant disorders, such as cancer. More importantly, they can present antagonistic functions, increasing their complexity. This review aims to summarize the existing data on the role of PKC in leukemia, specifically in CML. Through this review, we intend not only to show evidence for the involvement of PKC in CML development but also to raise new questions on whether PKC plays similar roles in other cancers.

**Overall role of PKC in cancer**

The aberrant regulation of different PKC isoforms has been associated with the development of many human diseases. Augmented levels and/or increased activation of PKCs have been linked not only to the malignant transformation of various cancer cell lines and tumors — including breast, ovarian, skin, lung, and gastric carcinomas — but also to aggressive and/or resistant subtypes. The classic PKCs, including PKCα, PKCβI, and PKCβII, have been shown to be overexpressed in early stage colon cancer, and have been associated with the proliferation of human breast cancer cell lines. PKCε and PKCζ have been reported to be overexpressed in primary tumors and cell lines that were derived from human non-small-cell lung cancers, and they also contribute to cellular proliferation in squamous cell carcinoma. With regard to aggressiveness, PKCη has been linked to prostate cancer development and metastasis. PKCδ has been correlated to cell growth, invasion and metastasis in breast cancer. Also in breast cancer, PKCε expression was correlated with important factors, such as HER2 levels or low survival rates, demonstrating that this PKC isoform could also be used as a prognostic factor.

PKCs have also been implicated in the alteration of hematopoietic stem cell (HSC) maturation. In addition, deregulation in PKC signaling represents an important feature during leukemia development. Survival of acute leukemic blasts was found to be mediated by PKC signaling through PDK1 activation. Moreover, the classic PKC isoforms are also associated with survival and poor prognosis in acute myeloid leukemia. A large number of studies indicate that PKC plays a central role in chronic lymphocytic leukemia development, making it a potential target for chronic lymphocytic leukemia therapy. PKCε was reported to play a crucial role in the pathogenesis of hairy cell leukemia. Moreover, PKCβ overexpression has been correlated with worsened prognosis in patients with lymphoid malignancies. In addition, the alpha and theta isoforms of PKC have been studied in the context of bone marrow transplantation. These examples indicate that alteration in PKC regulation may be important for the development of both solid tumors and hematological malignancies.
Chronic myeloid leukemia: a brief review

Chronic myeloid leukemia (CML) is characterized by the clonal hyperproliferation of immature blood cells. CML represents approximately 20% of all adult leukemia cases. Depending on the amount of immature cells in the peripheral blood, CML can be clinically divided into three phases: chronic, accelerated, and blastic crisis. The course of CML development has also been molecularly divided into chronic and advanced phases based on gene-expression changes. The rearrangement of the chromosomes 9 and 22 is a hallmark of CML. This abnormality, known as the Philadelphia (Ph) chromosome, is present in approximately 95% of all CML patients.

The t(9;22)(q34.1;q11.21) translocation that produces the Ph chromosome results in the fusion of the BCR and ABL genes. The chimeric gene BCR-ABL encodes a protein with constitutive tyrosine-kinase (TK) activity. The BCR-ABL oncprotein constitutively activates several downstream pathways, including the phosphatidylinositol-3 kinase (PI3K)/Akt, Ras/Raf/MAPK and JAK/STAT pathways. These pathways are responsible for the induction of cellular proliferation, loss of adhesion, blockage of cellular differentiation, and inhibition of programmed cell death. Through these cellular effects, the BCR-ABL oncprotein has been described as the main effector of CML cellular transformation.

CML is considered an excellent model for studying cancer development, because it harbors only one biomarker responsible for disease establishment and evolution. Therefore, deciphering the role of PKC in this cancer model could help answer several unresolved questions on CML development and provide possible insights into the role of PKC in other cancers.

Involvement of PKC in CML cellular alterations

BCR-ABL has been reported to block important signaling pathways crucial for blood stem cell maturation. Patients with CML exhibit accumulation of immature blood cells known as blasts in the peripheral blood; these cells do not present their normal functions, as they are not fully differentiated. As a consequence, CML patients may present immunodeficiency, which is associated with several defects presented by the immature blasts, such as internalization of ligands, degranulation, microbicidal killing, and alterations in chemotaxis and adhesion. PKC has been described as playing a role in HSC maturation, specifically during the formation of mature granulocytes and dendritic cells. Additionally, deficiency in granulocytes and dendritic cells has been associated with decreased immunity, as evidenced primarily by antigen cell defense in the case of granulocyte deficiency and decreased T-cell activation in the case of dendritic cell deficiency. Although there is no evidence that directly links PKC to CML cellular events, several studies have indicated that both PKC-mediated and BCR-ABL-mediated signaling pathways may produce similar changes in cellular phenotypes. Therefore, further investigation is warranted to understand the role of PKC- and BCR-ABL-mediated signaling in CML cellular transformation.

CML patients exhibit high levels of PKC in erythrocytes compared with normal individuals. Moreover, PKC activity is also increased in CML patients, as shown by increased PKC phosphorylation. This alteration in PKC activity may be one of the factors responsible for altered thermal sensitivity and mechanical stability of CML erythrocytes.

The in vitro proliferation of T cells can be stimulated by the direct activation of PKC together with intracellular calcium signaling, suggesting that PKC may play an important role in immune defense mechanisms in CML patients.

A significant decrease in the amount of PKCα was demonstrated in CML cells relative to normal neutrophils, whereas PKCδ was highly expressed in CML neutrophils compared with controls. Indeed, alterations in protein phosphorylation have been observed in CML neutrophils under stimulation with phorbol 12-myristate 13-acetate, a direct activator of PKC, further supporting a role for PKC signaling in CML cells. Furthermore, the alpha, beta, iota, theta, and mu isoforms of PKC are present at low levels in the cytosol of CML cells, and their respective kinase activities are also significantly decreased. Taken together, these data suggest that PKC activity may affect the phenotypes of CML blood cells, mainly in their maturation and immunological functions.

PKC signaling in CML cells

The oncprotein BCR-ABL is a constitutively active TK that triggers several signaling pathways in CML cells through uncontrolled phosphorylation activity. Together, PKCs also play an important role in numerous cancer signaling pathways, including those downstream of the BCR-ABL oncprotein (Figure 2). PKCi is one of the BCR-ABL downstream targets, and has been demonstrated to confer resistance to apoptosis in vitro after treatment with the anticancer drug Taxol® (Bristol-Myers Squibb, New York, NY, USA). In addi-
Ectopic expression of BCR-ABL can modulate the expression of PKC isoforms. These alterations have also been similarly found in the original CML cells.\textsuperscript{45,47} The induction of PKC\textgreek{i} has been shown to be dependent on MEK1/2 activity, but not on PI3K or p38 MAPK activity.\textsuperscript{50} PKC\textgreek{i} also participates in cellular differentiation by promoting the downregulation of BCR-ABL messenger ribonucleic acid transcription, which leads to decreased BCR-ABL protein expression. This downregulation of BCR-ABL appears to be driven by the MAPK pathway.\textsuperscript{44} IFN\textalpha; is known to be an activator of distinct signaling pathways, such as JAK/STAT.\textsuperscript{51} IFN\textalpha; is also a negative regulator of cell proliferation, in contrast to STAT3 and STAT5, which are constitutively activated in both CML patients and BCR-ABL-positive cell lines.\textsuperscript{52} Therefore, IFN\textalpha; treatment induces an antileukemic process through PKC\textgreek{5} mediated STAT1 activation.\textsuperscript{53}

Alterations in gene-expression profiles by BCR-ABL TK activity have also been extensively studied to identify potential biomarker(s) and improve our knowledge of CML development.\textsuperscript{53,54} Several genes have already been described as BCR-ABL targets that are essential for the phenotypic changes of CML cells, such as \textit{VEGF}, \textit{HIF1}, \textit{MCL1}, \textit{BCL2L1}, \textit{CCND1}, and \textit{COX2}.\textsuperscript{55,56,57,58}

PKC inhibition as a CML-treatment modality

Direct or indirect therapeutic inhibition of PKC isoforms alone or in conjunction with other therapeutic approaches has been the focus in many types of cancer. This is not surprising, since PKC isoforms are closely implicated in tumorigenesis. In vitro study of non-small-cell lung cancer showed that the indirect inhibition of PKC\textgreek{3} and PKC\textgreek{5} promoted by glycyrrhetinic acid induced apoptosis in the NCI-H460 cell line.\textsuperscript{59} PKC inhibition together with Twist1 signaling contributes to castration and enzalutamide resistance in prostate cancer.\textsuperscript{60} In G-protein-mutant uveal melanoma, the use of specific targeting of PKC and PI3K/AKT pathways may be a future treatment.\textsuperscript{61}

Regarding CML, recently the use of imatinib mesylate (IM; Gleevec\textsuperscript{®}; Novartis, Basel, Switzerland), dasatinib, and nilotinib has been approved for this disease therapy.\textsuperscript{62} These drugs are TK inhibitors that target the kinase domain of the
ABL protein. Clinically, their applications have led to disease remission, as evidenced by molecular, cytogenetic, and hematological data. During the early days of CML therapy, bryostatin was tested as a chemotherapeutic drug; it belongs to the family of macrocyclic lactones, and it is known as a potent activator of PKC. Experiments with bryostatin in CD34+ CML cells have demonstrated selective reduction of cell growth compared with control cells. Trichosanthin, a phytotherapeutic compound derived from the root of *Radix trichosanthis*, has been shown to synergistically promote IM-induced growth arrest and BCR-ABL downregulation in K562 cells. In addition, trichosanthin inhibits PKC activities as well as the PTK, procaspase-3, Hsp90 and NF-κB signaling pathways. The few reported studies evidence the existing gap in this field and the need for more studies focusing on PKCs’ role in CML.

**Role of PKC in CML therapeutic resistance**

Currently, a major focus of cancer research is to understand the cellular and molecular mechanisms underlying tumor-cell resistance to targeted molecular therapies. Despite advances in CML therapy, disease relapse still occurs in a subset of patients after IM treatment. Therapeutic resistance in CML has been divided into BCR-ABL-dependent and BCR-ABL-independent mechanisms. The first type is linked to mutations in the TK inhibitor-binding domains on BCR-ABL, whereas the second type is associated with parallel or constitutive signaling pathway activation that can be triggered by BCR-ABL activity as well as other mechanisms. The BCR-ABL-independent resistance mechanisms allow cancer cells to survive even under BCR-ABL inhibition.

Although the role of PKC in CML has not been extensively studied, recent evidence has shown a possible correlation between altered expression of PKC signaling proteins and therapeutic resistance in CML cells. Dufies et al observed the overexpression of AXL, a TK receptor and member of the TAM family, in IM-resistant CML cells, and showed that its overexpression is dependent on the alpha and beta isoforms of PKC, along with the constitutive activation of ERK1/2. Another study showed that the expression of ABCB1/MDR1, which is a biomarker of multidrug resistance, is dependent on PKC signaling and cyclooxygenase-2 induction.

To minimize the development of IM-resistant CML, the efficacy of combination treatments with two or more drugs has been tested in vitro. A recent study reported that bryostatin treatment prior to IM had a more potent antiproliferative effect on a BCR-ABL-positive cell line and primary CML CD34+ cells compared with IM treatment alone. Furthermore, *N*-benzyladriamycin-14-valerate (AD198), a novel PKC8 activator, has been shown to induce apoptosis in IM-resistant BCR-ABL-positive cells. AD198 has shown effectiveness against IM-resistant cells both alone and in combination with IM.

The occurrence of resistance in CML therapy is not only due to IM administration. It is known that cancer stem cells (CSCs) are more resistant to therapy. As expected, BCR-ABL-positive HSCs (CML HSCs) also have been described to be more resistant to IM therapy than mature cells, eg, due to enhanced self-renewal pathways. The compound TDZD-8, which inhibits both the PKC and FLT3 signaling pathways, promotes rapid induction of cell death in BCR-ABL-positive HSCs with low toxicity for normal HSCs and progenitor cells. This result could show great promise in overcoming IM resistance. Nevertheless, activation of several PKC isoforms in combination with antileukemic treatment has been shown to improve the desired antileukemic effect in CML cells. Robert et al observed an increase in autophagic cell death that was promoted by acadesine, which is an adenosine monophosphate-activated protein-kinase activator, when any one of the alpha, beta, or gamma isoforms of PKC was activated in CML cell lines. Pellicano et al also demonstrated that BMS-214662, a farnesyl-transferase inhibitor, induced apoptosis in primitive CML cells (CD34+, CD34+CD38−), and that this event was dependent on PKCβ upregulation. Therefore, these findings indicate the involvement of different PKC isoforms in CML cell drug resistance, thus highlighting the need for further studies to elucidate the complex role of PKC signaling in CML.

**Present and future perspectives: the stem cell problem**

Both the aforementioned contradictory studies bring attention to several relevant questions in cancer study today and for coming years. What are the differences and similarities that CSCs share with normal stem cells? How do they support tumors? How can we interfere to achieve the best cost–benefit result for sensibility and specificity? Since we do not have full comprehension regarding the normal stem cell, it is difficult to apply the knowledge acquired so far to complete this puzzle. We only have some pieces that still do not make total sense, but hopefully they will. With this in mind, it is clear that CML HSCs could share more features with normal HSCs or other stem cells (embryonic or pluripotent) than just self-renewal pathways. The answer to this question relies on future knowledge regarding normal
stem cells and CSCs, and more importantly signaling from the microenvironment. Stem cells depend deeply on the microenvironment in order to present their normal function. Altered signaling from CML stroma has been proven to have a highly relevant role in disease development and maintenance, specially through mesenchymal stem cells (MSCs). Microenvironmental study has gained more importance over the years, but despite this, PKCs’ role in MSCs has only been studied in an MSC protective therapy context. It is certainly imperative that this field receive more attention in future.

Despite microenvironmental understanding, recently studies on stem cells have been trying to uncover more information in order to complete the puzzle. It has been described that some PKC isoforms are related to stem cell features, such as self-renewal and differentiation. In the normal context of HSCs, Sengupta et al showed that atypical PKCs are dispensable for the polarization and activity of mammalian HSCs in vivo, suggesting that an alternative tissue-specific and context-dependent signaling complex may be involved in controlling stem cell fate. This should be taken seriously, as the search for these other mechanisms could bring novel insights concerning normal stem cells.

In cancer, Chen et al demonstrated that CSC-like populations derived from multiple types of human primary tumors from human cancer cell lines and from transformed human cells required PKCδ activity, and PKC inhibition efficiently prevented tumor-sphere outgrowth from tumor-cell cultures, and also inhibited human CSC growth in vivo in a mouse xenograft model. Unfortunately, CML was not included in these models. Moreover, the authors highlighted that PKCδ is not required for the proliferation or survival of normal cells, suggesting the potential tumor-specificity of a PKCδ-targeted approach. This study was driven in CSC-like models; insofar as it was not performed in CSCs freshly isolated from tumors, the question about PKC involvement in this context still remains.

As presented, there are few studies focusing on PKCs’ role in CML HSCs, and no studies so far investigating PKCs in the CML microenvironment. However, taking other cancers as models, it is easy to identify the major challenge that is ahead of us.

**Conclusion**

Deregulation of PKC signaling has been linked to several types of cancer, including chronic myeloid leukemia. In vitro and in vivo data have shown that BCR-ABL and PKC function together to drive important molecular and cellular changes in CML cells. Initial studies revealed that administration of PKC inhibitors in conjunction with conventional CML therapy improved disease remission, as shown by molecular, cytogenetic, and hematological evidence. Nevertheless, recent reports have shown controversial findings, specially regarding CML resistance in more primitive cells. Taken together, the current findings demonstrate that further studies are necessary in order to achieve a better understanding of PKCs’ role in CML.

**Author contributions**

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

35. Michor F. Chronic myeloid leukemia blast crisis arises from progenitors.
57. Hickey FB, Cotter TG. BCR-ABL regulates phosphatidylinositol
3-kinase-p110γ transcription and activation and is required for prolifer-
 cells identifies a molecular signature of chronic myeloid leukemia blast
59. Song J, Ko HS, Sohn EJ, et al. Inhibition of protein kinase C α/βII
 and activation of c-Jun NH2-terminal kinase mediate glycyrhetinic acid
 induced apoptosis in non-small cell lung cancer NCI-H460 cells. Bioorg
 kinase C Twist1 signaling augments anticancer effects of androgen
depression and enzalutamide in prostate cancer. Clin Cancer Res.
61. Musi E, Ambrosini G, De Stanchina E, Schwartz GK. The phospho-
inositide 3-kinase selective inhibitor, AEB071, enhances the effect of the
protein kinase C inhibitor, AEB071, in GNAQ/GNA11 mutant
62. Swords R, Alvarado Y, Giles F. Novel Abl kinase inhibitors in chronic
myeloid leukemia in blast phase and Philadelphia chromosome-
mechanisms of resistance to imatinib (STI571) therapy. Leukemia.
64. Szalassi Z, Denning MF, Smith CB, et al. Bystoatin 1 protects protein
kinase C-delta from down-regulation in mouse keratinocytes in paral-
lel with its inhibition of phorbol ester-induced differentiation. Mol
 on chronic myeloid leukemia-derived haematopoietic progenitors.
p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic
67. Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinib mesy-
late, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-
N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug
68. Binato R, Mencalha A, Pizzatti L, Schoell V, Zalcberg I, Abdelhay E.
RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Mol
pression and function in imatinib-resistant chronic myeloid leukemia
70. Kalle AM, Sachchidanand S, Pallu R. Bcr-Abl-independent mechanism
of resistance to imatinib in K562 cells: induction of cyclooxygenase-2
(COX-2) by histone deacetylases (HDACs). Leuk Res. 2010;34:
1132–1138.
 cell elimination in vitro by bryostatin priming with imatinib mesylate.
72. Lotheinstein L, Savranskaya L, Sweatman TW. N-benzyladriamycin-14-
valerate (AD 198) cytotoxicity cirkuntions Bcr-Abl anti-apoptotic
signaling in human leukemia cells and also potentiates imatinib
73. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of
leukemia stem and progenitor cells induced by the compound 4-benzyl,
2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007;110:
4436–4444.
ogenous leukemia (CML) cells through PKC-dependent induction of
75. Pellicano F, Copland M, Jørgensen HG, Mountford J, Leber B,
Holyoake TL. BMS-214662 induces mitochondrial apoptosis in chronic
myeloid leukemia (CML) stem/progenitor cells, including CD34+38-
 cells, through activation of protein kinase Cβ. Blood.
of CML stem and progenitor cells from tyrosine kinase inhibitors
through N-cadherin and Wnt-β-catenin signaling. Blood. 2013;121:
1824–1838.
77. Higuchi S, Li M, Zhu P, Ashraf M. Delta-opioid receptor activation
promotes mesenchymal stem cell survival via PKC/STAT3 signaling
78. Song BW, Chang W, Hong BK, et al. Protein kinase C activation
stimulates mesenchymal stem cell adhesion through activation of focal
79. Tsai TL, Manner PA, Li WJ. Regulation of mesenchymal stem cell
chondrogenesis by glucose through protein kinase C- transfroming
2013;8: e54122.
(apPKCa and apPKCa) is dispensable for mammalian hematopoietic stem
cell activity and blood formation. Proc Natl Acad Sci U S A.
82. Chen Z, Forman LW, Williams RM, Faller DV. Protein kinase C-delta
inactivation inhibits the proliferation and survival of cancer stem cells